Goldman Sachs
RPID icon

Goldman Sachs’s Rapid Micro Biosystems RPID Stock Holding History

Goldman Sachs’s Portfolio RPID Stock Details RPID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-71,912
Closed -$163K – 6930
2026
Q1 		$163K Buy
71,912
+16,606
+30% +$60.8K ﹤0.01% 6133
2025
Q4 		$160K Buy
+55,306
New +$192K ﹤0.01% 6095
2024
Q2 		– Sell
-18,639
Closed -$18.1K – 5880
2024
Q1 		$18.1K Sell
18,639
-199,648
-91% -$194K ﹤0.01% 5400
2023
Q4 		$162K Sell
218,287
-729,494
-77% -$747K ﹤0.01% 5208
2023
Q3 		$1.02M Buy
947,781
+6,424
+0.7% +$6.38K ﹤0.01% 4257
2023
Q2 		$941K Sell
941,357
-2,983
-0.3% -$3.02K ﹤0.01% 4378
2023
Q1 		$1.24M Sell
944,340
-89,001
-9% -$116K ﹤0.01% 4227
2022
Q4 		$1.17M Buy
1,033,341
+1,003,400
+3,351% +$2.43M ﹤0.01% 4327
2022
Q3 		$97K Sell
29,941
-23,549
-44% -$91.4K ﹤0.01% 5689
2022
Q2 		$230K Buy
53,490
+22,545
+73% +$105K ﹤0.01% 5575
2022
Q1 		$210K Sell
30,945
-126,970
-80% -$935K ﹤0.01% 5856
2021
Q4 		$1.68M Buy
157,915
+24,402
+18% +$381K ﹤0.01% 4400
2021
Q3 		$2.47M Buy
+133,513
New +$2.76M ﹤0.01% 3995

Other funds holding RPID

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
AWGLSCP
ABG-WTT Global Life Science Capital Partners Central, Hong Kong, Hong Kong $8.55M AUM 12.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EFA
Evernest Financial Advisors Carmel, Indiana $478M AUM 24% 1-Year Est. Return
AI
Advent International Boston, Massachusetts $17.7B AUM 5.23% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $763M AUM 108.51% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Goldman Sachs's RPID Position: Q2 2026 in Review

Goldman Sachs sold out of Rapid Micro Biosystems (RPID) in Q2 2026, closing a stake of 71,912 shares — an estimated $163K sold.

Goldman Sachs first reported a position in RPID in Q3 2021 and held it in 13 quarters. The position peaked at $2.47M in Q3 2021. 34 funds tracked by Wall St. Rank hold RPID as of Q2 2026.

  • Goldman Sachs reported no remaining Rapid Micro Biosystems position as of Q2 2026 after selling out during the quarter.
  • Goldman Sachs sold 71,912 Rapid Micro Biosystems shares in Q2 2026, an estimated $163K.
  • Goldman Sachs first reported a position in Rapid Micro Biosystems in Q3 2021 and held it in 13 quarters.
  • Goldman Sachs's Rapid Micro Biosystems position peaked at $2.47M in Q3 2021.
  • 34 funds tracked by Wall St. Rank held Rapid Micro Biosystems as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.